Core Viewpoint - Swiss pharmaceutical companies are expected to align with Pfizer's pricing agreement with the U.S. due to pressure from the Trump administration for reduced drug prices [1] Industry Summary - The head of a significant Swiss chemical and pharmaceutical industry association indicated that the demand for lower drug prices from the U.S. government is influencing Swiss companies [1]